Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

ry and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The clinical stage products discovered by Cytopia Ltd (YM Australia since January 2010) include the JAK 1/2 inhibitor, CYT387, and the novel VDA molecule, CYT997. Both were developed internally at Cytopia from research led by Dr. Andrew Wilks who discovered and named the Janus kinases. Cytopia's earlier stage portfolio includes a JAK3 program that was the subject of a research collaboration underwritten by Novartis that concluded in 2009 with any further development residing exclusively with Novartis; an ongoing collaborative research project with the Melbourne-based Cooperative Research Centre for Cancer Therapeutics (CRC CTx) for the development of Cytopia's inhibitors of Focal Adhesion Kinase (FAK), a protein implicated in progression and metastasis of numerous solid tumors; and a novel series of compou
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2
... Kingdom and GAITHERSBURG, Md., Oct. 29 /PRNewswire/,-- ... name to MedImmune to,reflect AstraZeneca,s vision for ... will unite the resources and expertise from ... activities within the AstraZeneca,Group, under the "MedImmune" ...
... the Innovator in,Ultrasound for more than 50 years, announced ... for advanced cardiac and,vascular imaging, the ProSound Alpha 10 ... American Heart Association, at the Orange County,Convention Center in ... 7 and the Alpha 10 incorporate all of the ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a ... and stem cell research systems,today announced that Mr. ... a corporate presentation at the Acumen BioFin Rodman,& ... be held,November 5 - 7, 2007, at the ...
Cached Biology Technology:AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:8/20/2014)... awarded the Oklahoma Medical Research Foundation a five-year, $14.5 ... the bacteria,s effects on humans. , For 10 ... have studied the human immune response to anthrax bacteria ... The original funding came soon after anthrax-laced letters killed ... terrorist attacks of Sept. 11, 2001. , The ...
(Date:8/20/2014)... the past few years, Virginia Tech,s Wu Feng has ... grant from the "Computing in the Cloud" program, and ... $6 million award from the Air Force on "big ... NSF and the National Institutes of Health on "big ... together the "parallel computing" aspects from each grant, he ...
(Date:8/20/2014)... for electronically manipulating the flight muscles of moths and ... those muscles. The work opens the door to the ... emergency response. , "In the big picture, we want ... moths for use in applications such as search and ... of electrical and computer engineering at NC State and ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2
... for creating chemical reactions between single molecules, scientists ... (NIST) have employed microfluidicsthe manipulation of fluids at ... molecules of interest. By combining this new microfluidic ... multiple droplets and cause their molecular contents to ...
... Researchers at the National Institute of Standards and ... other government agencies, have produced a new reference ... used as a hardener in high-performance alloys and ... fatal illness. The new reference material is expected ...
... that dust from a nearby construction zone will harm your ... confirm your suspicions or better yet, set your mind at ... Sandra Chudnovsky, of TAU,s Department of Geography have developed a ... ― to help families and authorities monitor the quality ...
Cached Biology News:New nanochemistry technique encases single molecules in microdroplets 2New beryllium reference material for occupational safety monitoring 2Tel Aviv University invention busts dust 2Tel Aviv University invention busts dust 3
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
... PROTEAN II xi 2-D system runs both gel dimensions ... tube gels can be separated in a single run ... cooling core in much the same manner as the ... the second-dimension slab gels may be cast in the ...
Biology Products: